Form 4: Adaptive Biotechnologies Director Acquires Shares

Adaptive Biotechnologies Director Katey Einterz Owen acquired 15,625 shares of common stock on March 4, 2026, increasing her direct beneficial ownership to 88,254 shares.

Summary

• Director Katey Einterz Owen acquired 15,625 shares of Adaptive Biotechnologies Corp (ADPT) common stock.
• The transaction occurred on March 4, 2026.
• The acquisition price was $0 per share, indicating a grant or award rather than a market purchase.
• Following this transaction, Ms. Owen directly beneficially owns 88,254 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, which is a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as an insider's increased ownership, even through a grant, generally aligns management's interests with shareholders.

Positives

• An insider, Director Katey Einterz Owen, increased her direct beneficial ownership by 15,625 shares, aligning her interests further with shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled, non-discretionary acquisition.

Negatives

• The acquisition price was $0, meaning it was not a direct cash investment by the director at market value, but likely a compensation-related grant.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider acquisitions, even if compensation-related, can signal management's continued alignment with shareholder interests, particularly in the biotechnology sector where long-term development cycles are common.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment to the company's long-term success.

Key Dates

Recommendation

The filing reports a routine insider stock grant to a director, which is a common compensation practice. While it increases insider ownership, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It primarily confirms ongoing alignment of director interests with shareholders.

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Acquisition, Director Ownership, Katey Einterz Owen, Rule 10b5-1